Patents by Inventor Ratish Gambhira

Ratish Gambhira has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies
    Patent number: 9388221
    Abstract: The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein o
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: July 12, 2016
    Assignees: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, The Johns Hopkins University
    Inventors: John T. Schiller, Diana V. Pastrana, Richard B. S. Roden, Ratish Gambhira, Douglas R. Lowy
  • Multi-component L2 vaccine for prevention of human papilloma virus infection
    Patent number: 9138470
    Abstract: Embodiments of the invention are directed to methods and compositions for generating an antibody response against HPV epitopes using multi-component vaccines. One such multi-component vaccine requires a T cell helper component and a toll-like receptor (TLR) agonist. In one embodiment, the inventors described a lipopeptide composition comprising an HPV L2 epitope.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: September 22, 2015
    Assignee: The Johns Hopkins University
    Inventors: Richard B. S. Roden, Ratish Gambhira, Hannah H. Alphs
  • PAPILLOMAVIRUS L2 N-TERMINAL PEPTIDES FOR THE INDUCTION OF BROADLY CROSS-NEUTRALIZING ANTIBODIES
    Publication number: 20130177585
    Abstract: The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein o
    Type: Application
    Filed: February 21, 2013
    Publication date: July 11, 2013
    Inventors: John T. Schiller, Diana V. Pastrana, Richard B.S. Roden, Ratish Gambhira, Douglas R. Lowy
  • Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies
    Patent number: 8404244
    Abstract: The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein o
    Type: Grant
    Filed: February 1, 2006
    Date of Patent: March 26, 2013
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Johns Hopkins University
    Inventors: John T. Schiller, Diana V. Pastrana, Richard B. S. Roden, Ratish Gambhira, Douglas R. Lowy
  • MULTI- COMPONENT L2 VACCINE FOR PREVENTION OF HUMAN PAPILLOMA VIRUS INFECTION
    Publication number: 20110177112
    Abstract: Embodiments of the invention are directed to methods and compositions for generating an antibody response against HPV epitopes using multi-component vaccines. One such multi-component vaccine requires a T cell helper component and a toll-like receptor (TLR) agonist. In one embodiment, the inventors described a lipopeptide composition comprising an HPV L2 epitope.
    Type: Application
    Filed: November 3, 2008
    Publication date: July 21, 2011
    Applicant: The Johns Hopkins University
    Inventors: Richard B. S. Roden, Ratish Gambhira, Hannah H. Alphs
  • Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies
    Publication number: 20090047301
    Abstract: The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein o
    Type: Application
    Filed: February 1, 2006
    Publication date: February 19, 2009
    Applicant: The Johns Hopkins University
    Inventors: John T. Schiller, Diana V. Pastrana, Richard B.S. Roden, Ratish Gambhira, Douglas R. Lowy